secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gossamer Bio, Inc. (GOSS)
CIK:        0001728117
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001728117-23-000133
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gossamer Bio Q3 net loss $40M, cash sufficient into H1 2026; PROSERA study ahead
--------------------------------------------------------------------------------

- Net loss $40.0M ($0.21/share) vs $59.4M loss in Q3 2022; R&D expenses $31.2M (down from $44.5M).
- Cash, equivalents & marketable securities $328.9M; expected to fund operations into first half of 2026.
- Phase 3 PROSERA site activations ahead of schedule; first patient dosing expected in Q4 2023.
- Additional TORREY open-label extension data (seralutinib in PAH) expected in Q4 2023.
- FRI sub-study of TORREY presented at ERS 2023; evidence of improved pulmonary blood vessel volume.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728117/000172811723000133/0001728117-23-000133-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728117/000172811723000133/goss-20231109.htm
  HTML page:      https://secwatch.observer/filing/0001728117-23-000133

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer